The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year ol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2015-12, Vol.61 (12), p.1835-1838
Hauptverfasser: van Werkhoven, Cornelis H., Huijts, Susanne M., Bolkenbaas, Marieke, Grobbee, Diederick E., Bonten, Marc J. M.
Format: Artikel
Sprache:eng
Schlagworte:
Age Factors
Aged
Aged, 80 and over
BRIEF REPORTS
Double-Blind Method
Female
Humans
Immunization
Infectious diseases
Male
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - immunology
Pneumonia
Treatment Outcome
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/civ686